JP2022518174A5 - - Google Patents

Info

Publication number
JP2022518174A5
JP2022518174A5 JP2021540019A JP2021540019A JP2022518174A5 JP 2022518174 A5 JP2022518174 A5 JP 2022518174A5 JP 2021540019 A JP2021540019 A JP 2021540019A JP 2021540019 A JP2021540019 A JP 2021540019A JP 2022518174 A5 JP2022518174 A5 JP 2022518174A5
Authority
JP
Japan
Prior art keywords
formulated
agent
agent according
skin
dinaca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021540019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518174A (ja
JP7631200B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012975 external-priority patent/WO2020146666A1/en
Publication of JP2022518174A publication Critical patent/JP2022518174A/ja
Publication of JP2022518174A5 publication Critical patent/JP2022518174A5/ja
Priority to JP2025017406A priority Critical patent/JP2025069381A/ja
Application granted granted Critical
Publication of JP7631200B2 publication Critical patent/JP7631200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021540019A 2019-01-11 2020-01-09 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ） Active JP7631200B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017406A JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791422P 2019-01-11 2019-01-11
US62/791,422 2019-01-11
PCT/US2020/012975 WO2020146666A1 (en) 2019-01-11 2020-01-09 N-acetylcysteine amide (naca) and (2r,2r')-3,3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017406A Division JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Publications (3)

Publication Number Publication Date
JP2022518174A JP2022518174A (ja) 2022-03-14
JP2022518174A5 true JP2022518174A5 (enExample) 2023-01-20
JP7631200B2 JP7631200B2 (ja) 2025-02-18

Family

ID=71521154

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540019A Active JP7631200B2 (ja) 2019-01-11 2020-01-09 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP2025017406A Pending JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017406A Pending JP2025069381A (ja) 2019-01-11 2025-02-05 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）

Country Status (6)

Country Link
US (1) US12458608B2 (enExample)
EP (1) EP3908271A4 (enExample)
JP (2) JP7631200B2 (enExample)
KR (1) KR102745520B1 (enExample)
CN (1) CN113573704A (enExample)
WO (1) WO2020146666A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017009584A2 (pt) 2014-11-07 2017-12-26 Nacuity Pharmaceuticals Inc tratamento de retinite pigmentosa com n-acetilcisteína amida
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
EP3908341A4 (en) 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
CA3167959A1 (en) * 2020-01-24 2021-07-29 Nacuity Pharmaceuticals, Inc. Prodrug for the treatment of disease and injury of oxidative stress
KR102693441B1 (ko) * 2021-05-26 2024-08-08 경북대학교 산학협력단 시스테인 유도체의 피부 미백 용도
EP4554560A1 (en) 2022-07-15 2025-05-21 Universidade de Coimbra Topical composition and uses thereof
EP4659758A1 (en) * 2023-01-31 2025-12-10 Mitsubishi Corporation Life Sciences Limited Anti-aging composition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340147A (en) 1965-06-28 1967-09-05 Mead Johnson & Co Amides of n-acylated cysteines
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US20030229141A1 (en) * 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
AU2002345699A1 (en) 2001-06-13 2002-12-23 Webb-Waring Institute For Biomedical Research A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
BE1014949A3 (fr) 2001-08-14 2004-07-06 Probiox Procede de detection de stress oxydant et trousse pour sa mise en oeuvre.
AU2003247144B2 (en) 2002-08-02 2007-11-29 Mor Research Applications Ltd. Treatment of multiple sclerosis with brain targeted anti oxidant compounds
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
JP2005350405A (ja) * 2004-06-11 2005-12-22 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
CN101232877A (zh) * 2005-04-21 2008-07-30 格伦·A·戈尔茨坦 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
US20090234011A1 (en) 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
JP4840804B2 (ja) 2006-01-20 2011-12-21 学校法人慶應義塾 酸化ストレスの判定方法
CA2741954A1 (en) 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US20120150029A1 (en) 2008-12-19 2012-06-14 University Of Miami System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
WO2011044230A2 (en) * 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
EP2397125A1 (en) * 2010-06-15 2011-12-21 Histocell, S.L. Antioxidant composition
US20120142550A1 (en) 2010-12-06 2012-06-07 Zehnder James L Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
WO2013138744A1 (en) 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
JP2016506391A (ja) 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
WO2014100361A1 (en) 2012-12-19 2014-06-26 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
EP3122342B1 (en) 2014-03-28 2020-09-23 NaCuity Pharmaceuticals, Inc. Method for the preparation of n-acetyl cysteine amide
BR112017009584A2 (pt) 2014-11-07 2017-12-26 Nacuity Pharmaceuticals Inc tratamento de retinite pigmentosa com n-acetilcisteína amida
US11268964B2 (en) 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
CA3017797A1 (en) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
CN111386255B (zh) 2017-09-20 2021-11-23 纳崔泰制药有限公司 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法
US20200253867A1 (en) 2017-09-22 2020-08-13 University Of Florida Research Foundation Devices and methods for reducing cystine crystals in vivo
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US20200281944A1 (en) 2017-11-17 2020-09-10 Mahmood Piraee Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders
CN108618993B (zh) * 2018-07-16 2021-07-27 广东格烯生物科技股份有限公司 一种美白组合物及其制备方法和应用
US12599577B2 (en) 2018-11-16 2026-04-14 University of Pittsburgh—of the Commonwealth System of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
EP3908341A4 (en) 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement

Similar Documents

Publication Publication Date Title
JP2022518174A5 (enExample)
JP2023145734A5 (enExample)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP2020023549A5 (enExample)
JP2005508840A5 (enExample)
RU2017119230A (ru) Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
CA2442168A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2014031964A1 (en) Composition for the treatment of migraine headaches
Dougherty et al. Gabapentin: a unique anti-epileptic agent
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
Majewski A current opinion on the safety and efficacy of doxycycline including parenteral administration–A review
JP2005525409A5 (enExample)
KR20090119760A (ko) 알츠하이머형 인지증의 예방 및 치료를 위한 의약
JP2024061731A (ja) 片頭痛の予防及び治療に使用するための栄養補助食品
JP2016505050A5 (enExample)
US20140105878A1 (en) Compositions and methods for prevention and treatment of migraines
JP2004091473A (ja) 色素沈着改善治療薬
US7790203B2 (en) Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
US3928578A (en) Composition for control of white muscle disease
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
Binnick Pityriasis rubra pilaris responding to aminonicotinamide
KR102615988B1 (ko) 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체
CA2893836A1 (en) A combination medicament comprising phenylephrine and paracetamol
JPH04342528A (ja) アルコール代謝およびアセトアルデヒド代謝促進剤